



OPEN ACCESS

APPROVED BY

Frontiers Editorial Office,
Frontiers Media SA, Switzerland

*CORRESPONDENCE

Andrea Sartore-Bianchi
andrea.sartorebianchi@unimi.it

[†]These authors have contributed
equally to this work and share
first authorship

SPECIALTY SECTION

This article was submitted to
Cancer Genetics,
a section of the journal
Frontiers in Oncology

RECEIVED 18 January 2023

ACCEPTED 07 March 2023

PUBLISHED 28 March 2023

CITATION

Mauri G, Patelli G, Gori V, Lauricella C, Mussolin B, Amatu A, Bencardino K, Tosi F, Bonazzina E, Bonoldi E, Bardelli A, Siena S and Sartore-Bianchi A (2023) Corrigendum: Case report: MAP2K1 K57N mutation is associated with primary resistance to anti-EGFR monoclonal antibodies in metastatic colorectal cancer. *Front. Oncol.* 13:1147497.
doi: 10.3389/fonc.2023.1147497

COPYRIGHT

© 2023 Mauri, Patelli, Gori, Lauricella, Mussolin, Amatu, Bencardino, Tosi, Bonazzina, Bonoldi, Bardelli, Siena and Sartore-Bianchi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Corrigendum: Case report: MAP2K1 K57N mutation is associated with primary resistance to anti-EGFR monoclonal antibodies in metastatic colorectal cancer

Gianluca Mauri^{1,2,3†}, Giorgio Patelli^{1,3†}, Viviana Gori^{1,3},
Calogero Lauricella³, Benedetta Mussolin⁴, Alessio Amatu³,
Katia Bencardino³, Federica Tosi³, Erica Bonazzina³,
Emanuela Bonoldi³, Alberto Bardelli^{4,5}, Salvatore Siena^{1,3}
and Andrea Sartore-Bianchi^{1,3*}

¹Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, Milan, Italy, ²IFOM, Istituto Fondazione di Oncologia Molecolare ETS, Milan, Italy, ³Department of Hematology, Oncology, and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milan, Italy, ⁴Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Torino, Italy, ⁵Department of Oncology, Università degli Studi di Torino, Turin, Italy

KEYWORDS

MAP2K1, MEK, panitumumab, resistance mechanisms, colorectal cancer

A Corrigendum on

Case report: MAP2K1 K57N mutation is associated with primary resistance to anti-EGFR monoclonal antibodies in metastatic colorectal cancer

by Mauri G, Patelli G, Gori V, Lauricella C, Mussolin B, Amatu A, Bencardino K, Tosi F, Bonazzina E, Bonoldi E, Bardelli A, Siena S and Sartore-Bianchi A (2022) *Front. Oncol.* 12:1030232.
doi: 10.3389/fonc.2022.1030232

Incorrect Affiliation

In the published article, there was an error regarding the affiliations for Alberto Bardelli. Affiliation 2 should be removed from Alberto Bardelli. As well as having Affiliation 4, Alberto Bardelli should also have the following new affiliation *Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Torino, Italy*.

There was also an error regarding the affiliation for Benedetta Mussolin. Affiliation 4 should be removed, and the new affiliation [*Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Torino, Italy*] should be added.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated

organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.